PLRZ (polyrizon-biotech.com) Forward P/S Multiple

Corporate emblem and logo of Polyrizon (PLRZ)

Polyrizon Ltd generates revenue by creating nasal sprays that block allergens and viruses. Business scalability is driven by royalties from partners without the need for capital expenditure on manufacturing plants. Reliable international routes ensure the uninterrupted delivery of bioccomponents. The forward P/S trend reflects a market revaluation of assets, with the value stabilizing at 0.00, providing a real-time assessment of current demand for the securities.

Polyrizon Limited - PLRZ Forward P/S Multiple (period 10/30/2024 - 10/30/2024)

Summary analytical data breakdowns for polyrizon-biotech.com (PLRZ)

- market price and analyst price targets:
Price Chart Polyrizon|PLRZ - Forecast Levels Chart
- business market valuation indicators:
Market Capitalization Polyrizon|PLRZ - Value Adjusted for Debt and Cash
- issuer book value statistics:
Book Value per Share Polyrizon|PLRZ - Book Capitalization|Market Value to Book Value Ratio polyrizon-biotech.com|PLRZ - Aggregate Asset Value
- debt and solvency information:
Debt to Equity Polyrizon Ltd|PLRZ - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Polyrizon|PLRZ - Company Aggregate Debts|Debt to Book Capitalization Ratio Polyrizon|PLRZ - Long-Term Liabilities|Company Short-Term Debt Polyrizon|Quick Liquidity polyrizon-biotech.com
- financial results and valuation multiples details:
PLRZ - Company Net Income|Future Profit Polyrizon Ltd|PLRZ - Market Cap to Earnings|Future Price to Earnings Polyrizon|PLRZ - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Polyrizon|PLRZ - Operating income before deduction of amortization|Net earnings per share for the last 12 months Polyrizon|PLRZ - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months polyrizon-biotech.com|PLRZ - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Polyrizon Ltd
- total revenue and sales volume data:
PLRZ - Company Sales Volume|Company Future Sales Volume Polyrizon|PLRZ - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Polyrizon
Fundamental company analysis:PLRZ (Polyrizon Ltd.)
Original product of polyrizon-biotech.com

The robotization of bio-barrier synthesis and the automation of packaging at Polyrizon Ltd (PLRZ) directly drive revenue dynamics, as reflected in the forward P/S valuation history. The current value of 0.00 demonstrates the ratio of market capitalization to expected sales, allowing investors to assess the premium paid for future commercial success and verify market demand for the issuer's high-tech solutions.

Direct competitors

Price-to-Projected Revenue Ratio Vertex VRTX|ALNY (Alnylam Pharmaceuticals, Inc.) - Future Price to Revenue|Insmed Inc - Forward P/S Multiple|Forward Price to Sales UTHR (United Therapeutics Inc.)|BMRN: Forward P/S Multiple|bridgebio.com (BBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio BGM Group Limited|COGT: Forward Price to Sales|Price-to-Projected Revenue Ratio Xeris Biopharma Inc (XERS)|Forward Price-to-Revenue Multiple Keros Corp KROS|Forward P/S Multiple ARCT (Arcturus Therapeutics)|Forward P/S Multiple etonpharma.com ETON|KMDA - Price-to-Projected Revenue Ratio|Future Price to Revenue FULC|abeonatherapeutics.com (ABEO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Mereo BioPharma Group plc (MREO)|Price-to-Projected Revenue Ratio Protalix BioTherapeutics|Price-to-Projected Revenue Ratio PLRX|Forward Price-to-Revenue Multiple APLT (Applied Therapeutics, Inc.)|RNTX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Gelteq GELS|Forward Price to Sales AYTU|Chemomab - Forward P/S Multiple|Market Cap to Expected Sales Ratio SRx Health Solutions Inc. SRXH|AEZS (zentaris.com) - Forward Price-to-Revenue Multiple|Future Price to Revenue CYTH (Cyclo Therapeutics Inc.)|Price-to-Projected Revenue Ratio Inozyme Pharma Inc.|Market Cap to Future Revenue Ratio Reneo Pharmaceuticals, Inc RPHM|Price-to-Projected Revenue Ratio COSCIENS Biopharma Inc. (CSCI)